Medication is FDA approved. The objective of this project is to test the efficacy of solriamfetol for treating insomnia (alone and in combination with Cognitive Behavioral Therapy for Insomnia [CBT-I]). Ultimately, this study will test whether wake extension (regardless of how it is achieved) will consolidate sleep and improve sleep continuity.

The current proposal is for a one-year study to investigate whether solriamfetol can improve sleep continuity and daytime performance, alone and in combination with Cognitive Behavioral Therapy for Insomnia. It is expected (given a common mechanism [wake extension]) that both Cognitive Behavioral Therapy for Insomnia and treatment with solriamfetol will improve sleep continuity, and that such effects will potentially be additive.

Inclusion Criteria:

• Participants will meet the diagnostic criteria for Insomnia Disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM-5).

In addition, the complaint of disturbed sleep will meet the following criteria:

• ≥ 30 minutes to fall asleep (SL) and/or ≥ 2 awakenings per night of ≥ 15 minutes duration and/or wake after sleep onset (WASO) time of ≥ 30 minutes where total sleep time (TST) did not exceed 6 hours (unless sleep efficiency [SE] is ≤ 80%).
• The problem is present for > 3 nights per week.
• The problem duration exceeds ≥ 6 months.
• The complaint of impaired daytime function must include, although not limited to, the report of daytime fatigue, sleepiness, or both.
• Preferred regular sleep phase between 10:00 PM and 8:00 AM
• Must garner physician's assent from their primary care clinician

Exclusion Criteria:

• Use of medication expressly for the purpose of falling or staying asleep (e.g., trazodone/ desyrel, melatonin, Tylenol PM, Nyquil, Benadryl).
• Night shift work
• Compromised renal function
• Major Coronary Artery Disease and/or uncontrolled (with meds) Hypertension
• Planning to become pregnant, pregnant, and/or breastfeeding
• Unstable medical or psychiatric illness
• Symptoms suggestive of sleep disorders other than insomnia
• Polysomnographic data indicating sleep disorders other than insomnia
• Evidence of active illicit substance use, abuse, or dependence
• Use of CNS active medications that are for treatment of insomnia or are thought to have caused insomnia as a side effect
• Inadequate language comprehension
• Current or past experience with CBT-I
• No access to the computers, I-Pads, or the internet

The investigators do not plan on sharing IPD with other researchers.

Blinding only applies to the medication arm. The randomization schedule was developed by our statistician and sent directly to research pharmacy for implementation.

The four arms are as follows:

1. Solriamfetol + CBT-I
2. Placebo + CBT-I
3. Solriamfetol Only
4. Placebo Only

All conditions engage in monitoring and assessment.